Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App





MRI-Based Technology Maps Effects of COVID-19 on Body’s Key Organs

By HospiMedica International staff writers
Posted on 18 Jan 2021
The UK’s Medicines & Healthcare products Regulatory Agency (MHRA) approved the use of CoverScan MD, an MRI-based technology that maps the effects of COVID-19 on several of the body’s key organs.

With 1 in 20 COVID-19 patients predicted to experience ongoing symptoms, or “Long COVID”, CoverScan MD, developed by Perspectum Group (Oxford, UK), quickly and safely provides medical professionals with the information critically needed to assess and evaluate patients.

Long Covid affects 10-30% of people who have symptomatic infection with Sars-CoV-2 and is defined as symptomatic disease lasting longer than 12 weeks. More...
Patients typically have extreme fatigue, chest pain, breathlessness, muscle aches and brain fog, but there are many reported symptoms. Many of these patients have organ damage or impairment, and ways of managing this are currently being researched. Patients with Long COVID are often unable to work for long periods of time, posing a significant burden to the economy and public services.

CoverScan MD is a software suite that provides a comprehensive, one-stop-shop assessment to detect damage in the heart, liver, lungs, kidneys, pancreas, and spleen. This single, quick MRI exam eliminates the need for multiple individual or invasive tests. Healthcare professionals and patients are then provided with quantitative measurements and accurate information, enabling them to develop personalized treatment plans for the long-term care of patients. With the use of CoverScan MD, UK doctors will now have a technology to add to the arsenal of tools used to assess and evaluate patients with Long-COVID, while at the same time gain a greater understanding of its symptoms and long-term impact on different organ systems.

“The MHRA authorization of Coverscan is timely,” said Dr. Melissa Heightman, Consultant Respiratory Physician, UCL, and Head of North London Long COVID care services.
“UK experts and NICE are developing a COVID follow up pathway which provides equitable access and high-quality community-based triage with rapid access to diagnostics and multi-specialty services. We have seen over 800 patients in North London, and it would be very valuable for their clinical care to be able to access COVERSCAN results.”

Related Links:
Perspectum Group


Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Electrode Solution and Skin Prep
Signaspray
Cardiograph Device
PageWriter TC35
Imaging Table
Stille imagiQ2
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.